Progress report from the NIDA Addiction Research Center, Baltimore, Maryland.
D014151:Anti-Anxiety Agents; D002047:Buprenorphine / Q000627:therapeutic use; D004311:Double-Blind Method; D013759:Dronabinol / Q000031:analogs & derivatives; D004357:Drug Synergism; D006556:Heroin Dependence / Q000534:rehabilitation; D006801:Humans; D002189:Marijuana Abuse / Q000209:etiology; D008691:Methadone; D009293:Opioid-Related Disorders / Q000209:etiology / Q000534:rehabilitation; D010423:Pentazocine; D000074606:Smoking Prevention; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D019966:Substance-Related Disorders / Q000209:etiology*; D014309:Tripelennamine
D014151:Anti-Anxiety Agents; C011941:nabilone; D014309:Tripelennamine; D002047:Buprenorphine; D013759:Dronabinol; D010423:Pentazocine; D008691:Methadone